[Skip to Content]
[Skip to Content Landing]
Views 192
Citations 0
Comment & Response
June 27, 2017

Administration of Fibrinogen Concentrate During Cardiac Surgery

Author Affiliations
  • 1Department of Anesthesiology, VU University Medical Center, Amsterdam, the Netherlands
  • 2Department of Anaesthesia, Intensive Care Medicine, Emergency Medicine, and Pain Therapy, Vivantes Klinikum im Friedrichshain, Berlin, Germany
JAMA. 2017;317(24):2550-2551. doi:10.1001/jama.2017.6219

To the Editor The randomized clinical trial by Dr Bilecen and colleagues1 showed no benefit of fibrinogen (factor I) concentrate use compared with placebo on intraoperative blood loss in patients with bleeding following high-risk cardiac procedures. We believe that the results may unfairly characterize fibrinogen concentrate use.

First, the authors chose intraoperative blood loss as their primary study end point. However, intraoperative blood loss is less relevant in cardiac surgery than blood loss that occurs after chest closure.2 Unfortunately, 24-hour blood loss, which showed a significant reduction in the fibrinogen concentrate group, was a secondary end point.

First Page Preview View Large
First page PDF preview
First page PDF preview